论文部分内容阅读
自1996年3月至1999年3月,我们对89例晚期非小细胞肺癌(NSCLC)病人进行随机对照研究,以比较生物治疗方案[即康莱特十IFN-α-1b(赛若金)]与化疗方案(VP16+DDP即EP方案)的近期疗效、毒性以及病人生活质量的改善情况.
From March 1996 to March 1999, we conducted a randomized controlled study of 89 patients with advanced non-small cell lung cancer (NSCLC) to compare the biological treatment protocol [ie, Kanglaite 10 IFN-α-1b (Saruijin)] With the chemotherapeutic regimen (VP16+DDP or EP regimen), the short-term efficacy, toxicity, and improvement of the patient’s quality of life.